Laboratory research tools. CMLase is a protein-engineering advance, not yet a clinical therapy. Photo: Pexels.
Disclosure: This article discusses an experimental research enzyme. No product is currently available, and LongevityTortoise does not have an affiliate relationship with any CMLase developer. General supplement links below are disclosed as required and use rel="nofollow sponsored".
AGE-reduction supplements are not proven to replace medical treatment or reverse disease. Always consult a qualified healthcare professional before changing your health regimen.
What is glycation, and why does it matter for ageing?
Glycation is the chemical attachment of sugars to proteins, lipids or DNA. It happens continuously inside the body — and more rapidly when blood glucose is high — creating a family of damaged molecules called advanced glycation end-products (AGEs). Over time, AGEs accumulate on long-lived proteins such as collagen, crystallin in the eye lens, myelin in nerves, and basement membranes in blood vessels.
Because many of these proteins turn over slowly, AGEs can persist for years or even decades. The result is cross-linked, stiffened tissue that behaves like "biological concrete." In the lens, this contributes to cataracts; in arteries, it promotes vascular stiffness; in skin, it reduces elasticity; and in kidneys and nerves, it is implicated in diabetic complications. AGE accumulation is so closely tied to molecular ageing that it is sometimes described as a form of protein chemical ageing.
There are many AGE structures. The most studied include pentosidine, methylglyoxal-derived AGEs and Nε-carboxymethyl-lysine (CML). CML is one of the most abundant and chemically stable AGEs in human tissues, making it a high-value target for any intervention that aims to reverse molecular ageing rather than merely slow it.
Introducing CMLase: an enzyme designed to undo protein damage
CMLase is a newly engineered enzyme that specifically removes CML from proteins. It was created through a combination of bacterial enzyme mining, structure-guided protein engineering and directed evolution. The starting point was a naturally occurring enzyme family that could already cleave some glycation adducts, but with low activity or poor specificity for CML. Researchers then introduced mutations that widened the active site, improved binding to the CML-lysine adduct, and increased catalytic turnover.
The result is a protein that acts like a microscopic "lawnmower": it scans along a glycated polypeptide, recognises CML-lysine residues, and snips off the carboxymethyl group, restoring the original lysine side chain. In principle, this is a true reversal of the chemical damage, not merely an inhibition of new AGE formation.
What the July 2026 Nature Communications paper showed
In July 2026, Trabosh, Smith, Hsu and colleagues published "Reversal of protein chemical aging by enzymatic deglycation" in Nature Communications. The study reported several key findings:
- Specificity: CMLase acted on CML-lysine adducts with high selectivity and did not appear to damage the underlying protein backbone at the tested doses.
- Activity on human tissues: When applied to human tissue samples, including aged proteins from the eye lens and other long-lived tissues, CMLase reduced detectable CML levels by up to roughly 70% under optimised laboratory conditions.
- Reversal, not prevention: The enzyme removed existing AGEs rather than blocking the formation of new ones — a distinction that sets it apart from most current anti-glycation strategies.
- Proof of concept: The work demonstrated that at least one major AGE class, long considered chemically irreversible in vivo, can be enzymatically repaired.
This is not the same as proving human rejuvenation. The experiments were performed on isolated tissues and proteins, not living people. Delivery, dosing, safety, off-target effects and immune responses remain major unanswered questions. But the paper moved the field from "AGEs are irreversible" to "some AGEs can be reversed with the right enzyme."
| Strategy | How it works | Evidence level (as of Sept 2026) | Key limitation |
|---|---|---|---|
| CMLase | Enzymatic cleavage of existing CML-lysine adducts | Preclinical; human tissue ex vivo | No human in vivo data; delivery and safety unknown |
| Dietary AGE restriction | Reduces intake of pre-formed AGEs from grilled, fried and processed foods | Some human biomarker trials | Only affects new AGE input, not existing deposits |
| Carnosine / anserine | Anti-glycation dipeptide; may scavenge reactive carbonyls | Limited human data | Unclear how much reaches deep tissues or reverses damage |
| Benfotiamine / thiamine | Reduces formation of some AGEs in high-glucose settings | Diabetic complication trials | Prevention-focused; does not remove existing AGEs |
| Alagebrium / AGE breakers | Small molecules designed to break AGE cross-links | Disappointing human trials | Clinical efficacy not established |
Why CMLase could matter for longevity
The 2023 hallmarks of ageing framework includes disabled macroautophagy, chronic inflammation, cellular senescence and loss of proteostasis as drivers of ageing. AGE-damaged proteins sit at the intersection of several of these hallmarks. They are poorly degraded, trigger inflammatory signalling through receptors such as RAGE, and contribute to stiffened extracellular matrix.
If CMLase — or improved versions of it — can be delivered safely to human tissues, it could:
- Restore elasticity to aged arteries, skin and kidneys by removing cross-links from long-lived collagen.
- Reduce the AGE-driven inflammatory signalling linked to vascular and metabolic ageing.
- Protect the eye lens and nerve myelin from AGE accumulation over decades.
- Provide a research tool to test whether reversing protein damage improves tissue function, not just biochemistry.
None of this has been shown in living humans. The gap between ex vivo enzyme activity and a clinically useful therapy is large. But the paper opens a clear path: identify the right enzyme, engineer it, and ask whether clearing AGEs improves health.
Caveats: what CMLase is not
It is important to be clear about the limits:
- Not a human therapy yet. CMLase has not entered clinical trials. We do not know whether it can be delivered safely into human tissues, how often it would be needed, or whether the immune system would react to a bacterial-derived protein.
- Only one AGE. CMLase targets CML specifically. Other AGEs, such as methylglyoxal-derived hydroimidazolones or pentosidine cross-links, may require different enzymes or approaches.
- Tissue access is uncertain. An enzyme that works in a test tube or on an ex vivo lens must still cross cell membranes, survive degradation, and reach the right proteins in the right organs.
- Benefit is unproven. Removing CGE marks is biochemically impressive, but the crucial question — does it improve organ function or extend healthy lifespan? — remains open.
Supplement note: Several over-the-counter products claim to reduce AGEs or "fight glycation." As of September 2026, no dietary supplement has been proven to reverse established CML deposits in humans, and none should replace medical treatment. If you are considering anti-glycation supplements such as carnosine, benfotiamine or AGE-inhibiting antioxidants, discuss them with a healthcare professional first.
Watch: glycotoxins and protein damage in ageing
For a concise explanation of how dietary and endogenous AGEs form, and why they matter for healthy ageing, the NutritionFacts.org clip below summarises the science in plain English.
Practical, cautious takeaways
- Diet remains the best-proven lever. Cooking methods matter: boiling, steaming and stewing produce fewer dietary AGEs than grilling, frying and roasting at high heat.
- Blood sugar control helps. Keeping glucose excursions in check reduces the rate at which new AGEs form inside the body.
- Do not wait for CMLase. The enzyme is exciting research, but it is years away from any clinical use. Established approaches — exercise, sleep, blood pressure and glucose management — still have the strongest evidence for slowing molecular ageing.
- Be sceptical of supplement hype. Products marketed as "AGE blockers" or "anti-glycation" vary widely in quality and evidence. None have been shown to do what CMLase did in the laboratory.
FAQ
What is CMLase?
CMLase is an engineered bacterial enzyme that cleaves Nε-carboxymethyl-lysine (CML), a common advanced glycation end-product that accumulates on long-lived proteins as tissues age.
What did the July 2026 Nature Communications paper show?
Trabosh et al. reported that CMLase reduced CML marks by up to roughly 70% in human tissue samples, including proteins from the lens and other long-lived tissues, suggesting that at least some age-related protein damage can be enzymatically reversed.
Is CMLase available as a supplement or treatment?
No. As of September 2026, CMLase is an early-stage research tool. It has not been tested in human clinical trials, approved by regulators, or commercialised as a therapy or supplement.
References
- Trabosh N, Smith J, Hsu M Y-H, et al. Reversal of protein chemical aging by enzymatic deglycation. Nature Communications. 2026;7:75141. doi:10.1038/s41467-026-75141-2
- Phys.org. "Engineered enzyme erases a stubborn mark of aging by up to 70% in human tissue samples." 22 July 2026. Read article
- The Scientist. "Lawnmower-like Enzyme Rewinds Decades of Molecular Aging in Human Tissue." Read article
- Fight Aging!. "CMLase Enzyme Developed to Break Down CML Advanced Glycation Endproducts." July 2026. Read article
- Longevity Technology. "When irreversible no longer means forever." 14 July 2026. Read article
- Lifespan.io. "Engineered Enzyme Reverses Age-Related Protein Damage." 17 July 2026. Read article
Published 4 September 2026. This article is for informational purposes only and is not medical advice. Consult a qualified healthcare professional before starting any supplement or health intervention, especially if you are pregnant, breastfeeding, have a medical condition or take medication. LongevityTortoise is an independent research review site.